Patients with Growth-Related Disorders and Caregivers Prefer the Somapacitan Device to the Somatrogon Device: Results from a Randomized Crossover Study Assessing Device Preference and Ease of Use Following Simulated Injections.

Autor: Akhtar S; Devices & Digital Health, Novo Nordisk A/S, Søborg, Denmark., Berg B; Clinical Operations, Obesity, Liver Diseases & Devices, Novo Nordisk A/S, Søborg, Denmark., Medina J; Medical & Science, Devices & Digital Health, Novo Nordisk A/S, Søborg, Denmark., Gonczi MN; Human Factors, Research Collective, Tempe, AZ, USA., Hamilton S; Rare Endocrine Rare Renal Diseases, Novo Nordisk Inc, Plainsboro, NJ, USA., Hildebrand E; Human Factors, Research Collective, Tempe, AZ, USA., Kelepouris N; Rare Endocrine Disorders, Novo Nordisk Inc, Plainsboro, NJ, USA., Neergaard JS; Safety Surveillance, Cardiovascular Disease, Novo Nordisk A/S, Søborg, Denmark., Sværke C; Global Development, Novo Nordisk A/S, Søborg, Denmark., Ter-Borch G; Clinical Operations, Obesity, Liver Diseases & Devices, Novo Nordisk A/S, Søborg, Denmark., Rasmussen NK; Medical & Science, Devices & Digital Health, Novo Nordisk A/S, Søborg, Denmark.

Publikováno v: Medical devices (Auckland, N.Z.) [Med Devices (Auckl)] 2024 Oct 30; Vol. 17, pp. 427-439. Date of Electronic Publication: 2024 Oct 30 (Print Publication: 2024).